Vanguard Group’s Gain Therapeutics GANX Stock Holding History

Vanguard Group’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.84M	Buy	569,901 +35,549	+7%	+$94.9K	﹤0.01%	3582
2025 Q3	$946K	Hold	534,352	–	–	﹤0.01%	3804
2025 Q2	$962K	Buy	534,352 +279,362	+110%	+$517K	﹤0.01%	3753
2025 Q1	$487K	Buy	254,990 +77,915	+44%	+$173K	﹤0.01%	3891
2024 Q4	$382K	Buy	177,075 +31,858	+22%	+$63.9K	﹤0.01%	3998
2024 Q3	$258K	Hold	145,217	–	–	﹤0.01%	4095
2024 Q2	$186K	Buy	145,217 +25,853	+22%	+$67.1K	﹤0.01%	4176
2024 Q1	$450K	Buy	119,364 +30,979	+35%	+$128K	﹤0.01%	4043
2023 Q4	$289K	Buy	88,385 +18,105	+26%	+$50.3K	﹤0.01%	4164
2023 Q3	$231K	Buy	70,280 +6,162	+10%	+$23.4K	﹤0.01%	4228
2023 Q2	$287K	Buy	64,118 +11,513	+22%	+$56.2K	﹤0.01%	4246
2023 Q1	$254K	Buy	+52,605	New	+$215K	﹤0.01%	4282

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Vanguard Group's GANX Position: Q4 2025 in Review

Vanguard Group increased its Gain Therapeutics (GANX) stake by 6.7% in Q4 2025, buying an estimated $94.9K and bringing the position to 569,901 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3582.

Vanguard Group first reported a position in GANX in Q1 2023 and has held it in 12 quarters since. 48 funds tracked by Wall St. Rank hold GANX as of Q4 2025.

Vanguard Group held 569,901 shares of Gain Therapeutics worth $1.84M as of Q4 2025.
Vanguard Group bought 35,549 Gain Therapeutics shares in Q4 2025, an estimated $94.9K.
Gain Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3582 holding.
Vanguard Group first reported a position in Gain Therapeutics in Q1 2023 and has held it in 12 quarters since.
48 funds tracked by Wall St. Rank held Gain Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.